CTIS.eu › Cities › France › Marseille
Marseille
France
1,485 total trials
664 recruiting
Filter these 1,485 trials by phase, condition, sponsor and more.
Open in Search →
2023-509511-84-00
9
2014-03-19
Advanced HR+ breast cancer
2024-517622-25-00
5
2013-12-06
Patients with localized prostate cancer and high-risk features of rela
2023-507556-68-00
5
2013-07-26
Multiple Sclerosis
2024-516198-61-00
5
2013-06-05
Patients with high risk of relapse, ER+ and HER2- primary non-metastat
2024-515171-35-00
5
2011-07-06
Prostatic adenocarnicoma with high risk of recurrence
2024-514844-10-00
4
2010-03-18
Retinoblastoma
2024-513905-29-00
5
2008-10-16
Beta-thalassaemia
2024-514756-32-00
5
2007-03-19
High grade osteosarcoma
2024-514538-19-00
5
2025-11-26
Mastocytosis
2024-517254-99-00
4
2025-09-16
The patients enrolled in IMMUNORARE will be adult patients with 5 rar
2024-516916-93-00
3
2025-09-08
This study will be a Phase 1b, global, multicenter, open-label, 2-part
2024-516687-28-00
5
2025-06-06
Patients with GPA and inadequate response to standard of care therapy
2023-510559-41-00
4
2025-01-02
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2024-516641-39-00
7
2024-12-02
Acute Myeloid Leukemia
2023-505840-20-00
9
2024-08-16
B-Cell Acute Lymphoblastic Leukaemia
2023-507220-23-00
5
2024-07-26
Transthyretin Amyloidosis with Cardiomyopathy
2023-508730-34-00
9
2024-07-10
Non-small cell lung cancer (NSCLC):
- Locally advanced NSCLC where par
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
2023-505846-24-00
4
2024-04-08
acute myeloid leukemia
2024-513306-65-00
4
2024-03-13
URethral stenosis
2023-505829-14-00
5
2023-12-22
First recurrence glioblastoma
2024-511708-18-00
4
2022-12-06
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung c
2024-513535-24-00
9
2022-05-02
Refractory or Recurrent Solid Tumor
2024-512940-51-00
3
2021-11-24
Central Nervous System Tumors
Showing 1,201–1,224 of 1,485 trials